[1] Boehringer Ingelheim & EU-IPFF, “Life with IPF – an eBook,” [Online]. Available: https://
www.boehringer-ingelheim.com/file/28552/download?token=dBRrll77. [Accessed 13
April 2017].

[2] L. Nalysnyk, J. Cid-Ruzafa and P. Rotella, “Incidence and prevalence of idiopathic
pulmonary fibrosis: review of the literature,” Eur Respir Rev, vol. 21, no. 126, pp.
355-361, 2012.

[3] J. Cordier and V. Cottin, “Neglected evidence in idiopathic pulmonary fibrosis: from
history to earlier diagnosis,” Eur Respir J, vol. 42, p. 916–923, 2013.

[4] E. Meltzer and P. Noble, “Idiopathic pulmonary fibrosis,” Orphanet, March 2008.
[Online]. Available: http://www.orpha.net/consor/cgi-bin/Disease_Search.php?lng=EN&-data_id=7029&Disease_Disease_Search_diseaseGroup=Idiopathic-pulmonary-fibro-
sis&Disease_Disease_Search_diseaseType=Pat&Disease(s)/. [Accessed 13 April 2017].

[5] IPF World, “European IPF Charter,” [Online]. Available: http://www.ipfcharter.org/.
[Accessed 21 July 2015].

[6] B. Ley, C. Ryerson and E. Vittinghoff, “A multidimensional index and staging system for
idiopathic pulmonary fibrosis,” Ann Intern Med, vol. 156, no. 10, pp. 684-691, 2012.

[7] British Lung Foundation, “Idiopathic pulmonary fibrosis and other types of inter-
stitial lung disease,” 2014. [Online]. Available: http://spirohub.com/wp-content/

uploads/2015/10/BLF-patient-information-ILD-and-IPF.pdf. [Accessed 13 April 2017].

[8] NHS Choices, “Pulmonary Fibrosis (idiopathic),” [Online]. Available: http://www.nhs.uk/
conditions/pulmonary-fibrosis/Pages/Introduction.aspx. [Accessed 13 April 2017].

[9] National Heart, Lung, and Blood Institute, “What Is Idiopathic ulmonary Fibrosis?,”
National Heart, Lung, and Blood Institute, 20 September 2011. [Online]. Available:
https://www.nhlbi.nih.gov/health/health-topics/topics/ipf/. [Accessed 13 April 2017].

[10] Pulmonary Fibrosis Foundation, “Patient Information Guide,” Pulmonary Fibrosis
Foundation, 2015. [Online]. Available: http://www.pulmonaryfibrosis.org/docs/
default-source/patient-information-guides/pff_patinfoguide_v0215.pdf?sfvrsn=0.
[Accessed 13 April 2017].

[11] Roche, “Fight IPF Consultation Guide,” February 2017 [Online]. Available: http://www.fightipf.co.uk/content/dam/fightipf/files/en_gb/REU048%20Consultation_guide_UK.pdf. [Accessed 13 April 2017].

[12] Intermune, “Idiopatic Pulmunar Fibrosis in Europe,” [Online]. Available: http://www.osservatoriomalattierare.it/documenti/category/7-documenti-vari?download=13:sche-
da-fibrosi-polmonare-idiopatica. [Accessed 13 April 2017].

[13] AMA fuori dal buio, “IPF patients guide,” [Online]. Available: https://www.osserva-
toriomalattierare.it/documenti/category/2-linee-guida-sulle-malattie-rare?down-
load=14:ipf-guida-pazienti-e-familiari-2014. [Accessed 13 April 2017].

[14] Y. D. Haim, “IDIOPATHIC PULMONARY FIBROSIS,” FLORIDA MD, pp. 26-28, 2012.

[15] D. Lamas, S. Kawut and E. Bagiella, “Delayed access and survival in idiopathic
pulmonary fibrosis: a cohort study,” Am. J. Respir. Crit. Care Med, vol. 184, pp.
842-847, 2011.

[16] F. Bonella, M. Wijsenbeek and M. Molina-Molina, “European IPF Patient Charter:
unmet needs and a call to action for healthcare policymakers,” Eur Respir J., vol. 47,
no. 2, pp. 597-606, 2016.

[17] V. Cottin and J. Cordier, “Velcro crackles: the key for early diagnosis of idiopathic
pulmonary fibrosis?,” European Respiratory Journal, vol. 40, pp. 519-521, 2012.

[18] Global Initiative for Chronic Obstructive Lung Disease, “GOLD Spirometry Guide,”
2010. [Online]. Available: http://goldcopd.org/wp-content/uploads/2016/04/GOLD_
Spirometry_2010.pdf. [Accessed 13 April 2017].

[19] Azienda Sanitaria Universitaria Integrata di Trieste, “Fibrosi polmonare,” 3 July 2016.
[Online]. Available: http://www.aots.sanita.fvg.it/aots/InfoCMS/RepositPubbl/table34/16/
Allegati/fibrosi%20polmonare.pdf. [Accessed 13 April 2017].

[20] Canadian Pulmonary Fibrosis Foundation, “Support Group Toolkit,” [Online]. Available:
http://cpff.ca/get-involved/support-group-toolkit/. [Accessed 13 April 2017].

[21] G. Raghu, H. Collard and J. Egan, “An official ATS/ERS/JRS/ALAT statement:
idiopathic pulmonary fibrosis: evidence-based guidelines for diagnosis and
management,” Am J Respir Crit Care Med, vol. 183, p. 788–824, 2011.

[22] S. Tomassetti, S. Piciucchi and P. Tantalocco, “The multidisciplinary approach in the
diagnosis of idiopathic pulmonary fibrosis: a patient case-based review,” Eur Respir
Rev, vol. 24, no. 135, pp. 69-77, 2015.

[23] National Institute For Health and Care Excellence, “Idiopathic pulmonary fibrosis in
adults: diagnosis and management,” 12 June 2013. [Online]. Available: https://www.nice.org.uk/guidance/cg163/resources/idiopathic-pulmonary-fibrosis-in-adults-diagno-
sis-and-management-35109690087877. [Accessed 13 April 2017].

[24] EURORDIS, “Policy fact sheet - centres of expertise,” 2013. [Online]. Available: http://
www.eurordis.org/sites/default/files/publications/factsheet_Centres_Expertise.pdf.
[Accessed 13 April 2017].

[25] European Union Committee of Experts on Rare Diseases, “Recommendations
on Quality Criteria for Centres of Expertise for Rare Diseases in Member States,”
24 October 2011. [Online]. Available: http://ec.europa.eu/health/sites/health/files/
rare_diseases/docs/eucerd_centresexpertise_en.pdf. [Accessed 13 April 2017].

[26] European Medicines Agency , “Summary of product characteristics Ofev,” [Online].
Available: http://www.ema.europa.eu/docs/en_GB/document_library/EPAR_-_Product_
Information/human/003821/WC500182474.pdf. [Accessed 11 May 2017].

[27] European Medicines Agency, “Summary of product characteristics Esbriet,” [Online].
Available: http://www.ema.europa.eu/docs/en_GB/document_library/EPAR_-_Product_
Information/human/002154/WC500103049.pdf. [Accessed 11 May 2017].

[28] G. Raghu, B. Rochwerg and Y. Zhang, “An Official ATS/ERS/JRS/ALAT Clinical
Practice Guideline: Treatment of Idiopathic Pulmonary Fibrosis. An Update of the 2011
Clinical Practice Guideline,” Am J Respir Crit Care Med, vol. 192, no. 5, p. 644, 2015.

[29] B. Bradley, H. Branley and J. Egan, “Interstitial lung disease guideline: the British
Thoracic Society in collaboration with the Thoracic Society of Australia and New
Zealand and the Irish Thoracic Society,” Thorax, vol. 63, no. 5, pp. 1-58, 2008.

[30] C. Emery, R. Schein and E. Hauck, “Psychological and cognitive outcomes of a
randomized trial of exercise among patients with chronic obstructive pulmonary
disease,” Health Psychol, vol. 17, p. 232–240, 1998.

[31] V. De, B. Kessels and M. Drent, “Quality of life of idiopathic pulmonary fibrosis
patients,” Eur Respir J, vol. 17, p. 954–961, 2001.

[32] J. Lee, S. McLaughlin and H. Collard, “Comprehensive care of the patient with
idiopathic pulmonary fibrosis,” Curr Opin Pulm Med, vol. 17, no. 5, pp. 348-354, 2011.

[33] D. Lewis and J. Scullion, “Palliative and end-of-life care for patients with idiopathic pulmonary fibrosis: challenges and dilemmas,” Int J Palliat Nurs, vol. 18, no. 7, pp.331-337, 2012.

[34] J. Egan, “Follow-up and nonpharmacological management of the idiopathic pulmonary
fibrosis patient,” Eur Respir Rev, vol. 20, no. 120, pp. 114-117, 2011.

[35] J. Christie, L. Edwards and A. Kucheryavaya, “The Registry of the International Society
for Heart and Lung Transplantation: twenty-seventh official adult lung and heart-lung
transplant report – 2010,” J Heart Lung Transplant, vol. 29, p. 1104–1118, 2010.

[36] D. Kim, H. Collard and T. King, “Classification and natural history of the idiopathic
interstitial pneumonias.,” Proc Am Thorac Soc, vol. 3, pp. 285-292, 2006.

[37] KnowIPFnow, “Patient brochure: Living with idiopathic pulmonary fibrosis (IPF),”
2015. [Online]. Available: https://knowipfnow.com/modules/enabled/force-download/
download.php?url=%2Fipfmaterials%2FKnowIPFNowPatientBrochure.pdf. [Accessed
13 April 2017].

[38] M. Selman, G. Carrillo and A. Estrada, “Accelerated variant of idiopathic pulmonary
fibrosis: clinical behavior and gene expression pattern,” PLoS ONE, vol. 2, p. e482,
2007 2007.

[39] C. King and S. Nathan, “Idiopathic pulmonary fibrosis: effects and optimal management
of comorbidities,” Lancet Respir Med, vol. 5, no. 1, pp. 72-84, 2016.

[40] T. Corte, S. Wort and A. Wells, “Pulmonary hypertension in idiopathic pulmonary
fibrosis: a review,” Sarcoidosis Vasc. Diffuse Lung Dis, vol. 26, pp. 7-19, 2009.

[41] G. Raghu, V. C. Amatto, J. Behr and S. Stowasser, “Comorbidities in idiopathic
pulmonary fibrosis patients: a systematic literature review,” European Respiratory
Journal, vol. 46, p. 1113–1130, 2015.

[42] G. Sgalla, S. Cerri and R. Ferrari, “Mindfulness-based stress reduction in patients
with interstitial lung diseases: a pilot, single-centre observational study on safety and
efficacy,” BMJ Open Respiratory Research, vol. 2, p. e000065, 2015.